An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.

Inclusion Criteria:

- Currently receiving clinical benefit as defined by CR, PR or SD from treatment with
lapatinib through participation in a Phase I study of lapatinib either as monotherapy
or as part of a combination regimen.

- Ability to understand and provide written informed consent to participate in this
trial.

- Is male or female.

- Female and male subjects agree to the protocol specific birth control measures

Exclusion Criteria:

- Permanent discontinuation of lapatinib in the previous study due to intolerance or
treatment failure.

- Is a pregnant or lactating female.

- Is considered medically unfit for the study by the investigator as a result of the
medical interview, physical exam, or screening investigations.

- Currently receiving treatment with any medications listed on the prohibited
medication list (see Section 7.2).

- Has Class III or IV heart failure as defined by the New York Heart Association (NYHA)
functional classification system.

- Has a left ventricular ejection fraction (LVEF) < 40% based on MUGA or ECHO.